Select Bibliography

Filter by any of these (after searching):

Kaufmann, T.

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 5 items

BRAF–MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas

Brastianos, P.K. , Twohy, E. , Geyer, S. , Gerstner, E.R. ... - - N Engl J Med - 2023

Manuscript - Primary - Primary - Neuro-Onc - Alliance-A071601

NCCTG phase II trial of bevacizumab in combination with sorafenib (BEV/SOR) in recurrent glioblastoma (RGBM).

Galanis, E. , Anderson, S. K. , Lafky, J. M. , Kaufmann, T. J. ... - SNO - Neuro-oncology - 2011

Abstract - Primary - Primary - Neuro-Onc - NCCTG-N0776

Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial

Galanis, E. , Anderson, S. K. , Lafky, J. M. , Uhm, J. , Giannini, C. ... - - Clin Cancer Res - 2013

Manuscript - Primary - Primary - Neuro-Onc - NCCTG-N0776

NCCTG phase II trial of bevacizumab in combination with sorafenib in recurrent GBM.

Galanis, E. , Jaeckle, K. , Anderson, S. , Kaufmann, T. , Uhm, J. ... - ASCO - J Clin Oncol - 2010

Abstract - Primary - Primary - Neuro-Onc - NCCTG-N0776

Improved outcome in recurrent glioblastoma (RGBM) patients treated with bevacizumab (BEV) and sorafenib (SOR) is predicted by a greater drop in apparent diffusion coefficient (ADC) on MRI imaging.

Kaufmann, T. J. , Anderson, S. K. , Jaeckle, K. A. , Uhm, J. H. ... - SNO - 16th Annual Scientific Meeting of the Society for Neuro-Oncology in Conjunction with the AANS/CNS Section on Tumors - 2011

Abstract - Secondary-not-in-original - Primary - Neuro-Onc - NCCTG-N0776